KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Debt to Equity (2016 - 2020)

Neogenomics filings provide 11 years of Debt to Equity readings, the most recent being $0.19 for Q1 2020.

  • On a quarterly basis, Debt to Equity rose 376.23% to $0.19 in Q1 2020 year-over-year; TTM through Mar 2020 was $0.19, a 376.23% increase, with the full-year FY2019 number at $0.19, down 36.14% from a year prior.
  • Debt to Equity hit $0.19 in Q1 2020 for Neogenomics, down from $0.19 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.6 in Q2 2018 to a low of $0.01 in Q2 2019.
  • Median Debt to Equity over the past 5 years was $0.18 (2017), compared with a mean of $0.2.
  • Biggest five-year swings in Debt to Equity: tumbled 98.29% in 2019 and later surged 376.23% in 2020.
  • Neogenomics' Debt to Equity stood at $0.16 in 2016, then grew by 4.43% to $0.16 in 2017, then soared by 81.79% to $0.3 in 2018, then tumbled by 36.14% to $0.19 in 2019, then decreased by 0.8% to $0.19 in 2020.
  • The last three reported values for Debt to Equity were $0.19 (Q1 2020), $0.19 (Q4 2019), and $0.01 (Q3 2019) per Business Quant data.